Rizatriptan

Rizatriptan is a member of tryptamines. Among its listed roles, it functions as a serotonergic agonist, a vasoconstrictor agent and an anti-inflammatory drug. Functionally, it is related to N,N-dimethyltryptamine. Rizatriptan is a second-generation triptan and a selective 5-HT1B and 5-HT1D receptor agonist. Used in the treatment of migraines, rizatriptan was first approved in the US in 1998. Rizatriptan is available in oral tablets, orally disintegrating tablets (wafers), and oral film formulations. It is grouped under the following drug class(es): Serotonin agents and Triptans. Its therapeutic use is listed as analgesics and central nervous system (CNS) agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Rizatriptan benzoat, Risatriptan, rizatriptanum and MK 462 free base. Its PubChem CID is 5078.

CAS No 144034-80-0
Molecular Formula C15H19N5
Molecular Weight 269.34 g/mol
Synonyms N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine

Frequently Asked Questions